Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received carboplatin; half received paclitaxel weekly and half every 3 weeks. There were no between-group differences in progression-free survival. Ovarian ca...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 374; no. 8; pp. 738 - 748
Main Authors:	Chan, John K, Brady, Mark F, Penson, Richard T, Huang, Helen, Birrer, Michael J, Walker, Joan L, DiSilvestro, Paul A, Rubin, Stephen C, Martin, Lainie P, Davidson, Susan A, Huh, Warner K, O’Malley, David M, Boente, Matthew P, Michael, Helen, Monk, Bradley J
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 25.02.2016
Subjects:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Bevacizumab Bevacizumab - administration & dosage Carboplatin Carboplatin - administration & dosage Chemotherapy Clinical outcomes Disease-Free Survival Drug Administration Schedule Drug delivery Drug dosages Female Humans Infusions, Intravenous Intention to Treat Analysis Middle Aged Monoclonal antibodies Motivation Neuropathy Neutropenia Ovarian cancer Ovarian Neoplasms - drug therapy Paclitaxel Paclitaxel - administration & dosage Patients Survival Targeted cancer therapy United States > US California
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!